Immune Checkpoint Regulation and Signaling Pathways in Cancer
A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Immunology and Immunotherapy".
Deadline for manuscript submissions: 31 October 2025 | Viewed by 47
Special Issue Editor
Special Issue Information
Dear Colleagues,
In recent years, immunotherapy has revolutionized cancer treatment, especially with the advancement of immune checkpoint inhibitors. These medicines, which inhibit checkpoints (including PD-1, PD-L1, and CTLA-4), have demonstrated significant efficacy across many malignancies, resulting in extended survival for certain patients. Nonetheless, despite these advancements, considerable obstacles persist, including the development of resistance mechanisms, suboptimal response rates, and the necessity for more individualized treatment approaches.
This Special Issue, titled “Immune Checkpoint Regulation and Signaling Pathways in Cancer”, presents innovative research that tackles these significant concerns. It examines the molecular processes regulating immune checkpoint expression, the intricate interplay between tumor cells and the immune system, and novel therapeutic approaches for cancers resistant to checkpoint suppression. Furthermore, it underscores the significance of the tumor microenvironment, immune cell infiltration, and novel biomarkers that could inform future therapeutic strategies.
Our objective in assembling this Special Issue is to present a thorough examination of the present research landscape regarding immunological checkpoints in cancer biology and treatment, while also highlighting potential pathways that may result in next-generation immunotherapies. We are privileged to showcase contributions from renowned scientists in the area who will provide insights on diverse facets of immune checkpoint control, including the following:
- Mechanisms of immunological evasion and resistance to checkpoint inhibition.
- Signaling mechanisms regulating immune checkpoint expression.
- Innovative immunological checkpoints and immunoregulatory agents in oncological treatment.
- The involvement of tumor-infiltrating immune cells in regulating immunological responses.
- The prospects of combinatorial medicines and individualized cancer immunotherapy.
This Special Issue will be a crucial resource for researchers, clinicians, and students aiming to enhance their comprehension of immune checkpoint biology and investigate the most recent advancements in cancer immunotherapy. As we persist in elucidating novel aspects of immune modulation inside the tumor microenvironment, we are hopeful that these revelations may facilitate the development of more efficacious and enduring therapies for cancer patients globally.
This compilation of articles aims to encourage more interest and collaboration across several disciplines to tackle the current difficulties in the battle against cancer.
Dr. Sreeja C. Sekhar
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- tumor-immune evasion and interaction
- immune check point inhibition
- PD-1/PDL-1 pathway
- T-cell exhaustion and tumor microenvironment
- single-cell profiling
- therapeutic resistance
- tumor-infiltrating cells
- checkpoint inhibitors and immune modulation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
